Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001879894 | SCV002140367 | uncertain significance | Neu-Laxova syndrome 2 | 2022-09-07 | criteria provided, single submitter | clinical testing | This sequence change replaces threonine, which is neutral and polar, with methionine, which is neutral and non-polar, at codon 156 of the PSAT1 protein (p.Thr156Met). This variant is present in population databases (rs369944396, gnomAD 0.08%). This missense change has been observed in individual(s) with phosphoserine aminotransferase deficiency (PMID: 34089226). ClinVar contains an entry for this variant (Variation ID: 976941). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). Experimental studies have shown that this missense change affects PSAT1 function (PMID: 32077105). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Dudley Research Group, |
RCV001254449 | SCV001430428 | not provided | not provided | no assertion provided | research | ||
OMIM | RCV003991539 | SCV004811988 | pathogenic | PSAT deficiency | 2024-04-08 | no assertion criteria provided | literature only |